Cidara Therapeutics Inc

Cidara Therapeutics — 19th Annual Needham Virtual Healthcare Conference 2020

38 slides from Cidara Therapeutics's conference presentation, Apr 14, 2020

  1. Slide 1: New Hope for Serious Infections

    Slide 1: New Hope for Serious Infections

    New Hope for Serious Infections 19th Annual Needham Virtual Healthcare Conference Corporate Presentation April 14, 2020 © Cidara Therapeutics 2020

  2. Slide 2: Forward-Looking Statements

    Slide 2: Forward-Looking Statements

    Forward-Looking Statements clinical development or whether we will be able to These slides contain or whether it will transform the care of BMT patients; access BARDA funding; and whether our Cloudbreak whether the top line results of the STRIVE Part B clinical platform can be expanded to identify p

  3. Slide 3: Cidara investment thesis

    Slide 3: Cidara investment thesis

    SB 12 Cidara investment thesis Leading science on antifungal and antiviral prevention and treatment Rezafungin 1st antifungal in 13 years for 1st line treatment and prophylaxis Treatment – Phase 3 Transform treatment of candidemia and invasive candidiasis Prophylaxis – Phase 3 Transform prevention i

  4. Slide 4: Cidara's pipeline targets fungal and viral infections

    Slide 4: Cidara's pipeline targets fungal and viral infections

    Cidara’s pipeline targets fungal and viral infections IND- Program Proposed Indication Discov. in vitro in vivo enable Ph 1 Ph 2 Ph 3 ANTIFUNGAL Treatment of Rezafungin Candidemia & Invasive Candidiasis Prophylaxis of IFD in Rezafungin Blood & Marrow Transplant Patients ANTIVIRAL: CLOUDBREAK PLATFOR

  5. Slide 5: Cidara's pipeline targets multiple unmet medical needs

    Slide 5: Cidara's pipeline targets multiple unmet medical needs

    Cidara’s pipeline targets multiple unmet medical needs Rezafungin Cloudbreak 5

  6. Slide 6: Rezafungin: A novel echinocandin in Phase 3

    Slide 6: Rezafungin: A novel echinocandin in Phase 3

    Rezafungin: A novel echinocandin in Phase 3 Structural modification is designed to yield improved chemical & biological properties • Designed for prolonged PK once weekly dosing in clinical studies • Designed for high exposures potential for improved efficacy • Observed absence of toxic degradation

  7. Slide 7: Status of rezafungin phase 3 development plan

    Slide 7: Status of rezafungin phase 3 development plan

    Status of rezafungin phase 3 development plan Phase 3 Treatment Trial Phase 3 Prophylaxis Trial • Monitoring: We are monitoring a • Preparation: We are continuing number of factors affecting our regulatory and clinical activities enrollment and clinical trial to begin initiating sites and operations

  8. Slide 8: Rezafungin overall phase 3 development plan

    Slide 8: Rezafungin overall phase 3 development plan

    Rezafungin overall phase 3 development plan 1 Phase 3 Treatment Trial Phase 3 Prophylaxis Trial Treatment of candidemia & Prophylaxis against Aspergillus, Indication invasive candidiasis in patients Candida & PCP in allogeneic blood with limited treatment options and marrow transplant patients Phase

  9. Slide 9: STRIVE B Phase 2 data in candidemia & invasive candidiasis

    Slide 9: STRIVE B Phase 2 data in candidemia & invasive candidiasis

    STRIVE B Phase 2 data in candidemia & invasive candidiasis Corroborates STRIVE A results and supports ReSTORE Phase 3 9

  10. Slide 10: Rezafungin: Superior on time to negative blood culture

    Slide 10: Rezafungin: Superior on time to negative blood culture

    Rezafungin: Superior on time to negative blood culture Time to negative blood culture (mITT population) Rezafungin IV 400/200 100% 80% Caspofungin IV 60% Log-rank test: RZF vs CSP 40% p=0.02 20% Probability of of Probability negativecultureblood 0% 0 40 80 120 160 200 Hours since first dose Data on

  11. Slide 11: 30-Day All Cause Mortality – Post Hoc Analysis

    Slide 11: 30-Day All Cause Mortality – Post Hoc Analysis

    30-Day All Cause Mortality – Post Hoc Analysis* STRIVE Program: Rezafungin vs. Caspofungin FAVORS REZAFUNGIN FAVORS CASPOFUNGIN ReSTORE Phase 3 trial endpoint requires upper -8.8% limit of confidence -24.7% Rezafungin 400/200 +0.41% interval be below 20% threshold 95% confidence interval for FDA 20%

  12. Slide 12: Day 14 Clinical Response – Post Hoc Analysis

    Slide 12: Day 14 Clinical Response – Post Hoc Analysis

    Day 14 Clinical Response – Post Hoc Analysis* STRIVE Program: Rezafungin vs. Caspofungin FAVORS REZAFUNGIN FAVORS CASPOFUNGIN ReSTORE Phase 3 trial endpoint requires upper 9.9% limit of confidence 26.6% Rezafungin 400/200 -6.9% interval be below 20% threshold 95% confidence interval for EMA -20% Non

  13. Slide 13: ReSTORE trial design mirrors STRIVE

    Slide 13: ReSTORE trial design mirrors STRIVE

    ReSTORE trial design mirrors STRIVE All-Cause Mortality (1 ENDPOINT – FDA) Global Global Response Global Response & Global Global Global Response Global Global RResponseesponse ((11° EENDPOINTNDPOINT – EEMA)MA) All cause mortality RResponseesponse Response(1° ENDPOINT – FDA) Rezafungin Dose Option

  14. Slide 14: Our partner for Rezafungin ex-US/Japan

    Slide 14: Our partner for Rezafungin ex-US/Japan

    Our partner for Rezafungin ex-US/Japan 120 60 Over €2 50% MARKETS YEARS BILLION Over 50% revenue Active in Over 60 years of asset- European sales derived from new more than 30 led innovation exceeding €1 billion products launched in in Europe Over €2B ex-US the last five years in Europe 14

  15. Slide 15: Rezafungin collaboration recognizes commercial potential

    Slide 15: Rezafungin collaboration recognizes commercial potential

    Rezafungin collaboration recognizes commercial potential Data Available at Signing Rights Deal ($ million) ANTIFUNGAL P2 P3 NDA Marketed Cidara / Mundipharma: Rezafungin Ex-US; ex-Japan 568 Basilea / Pfizer: Ex-US; ex-Japan 725 ANTIBIOTICS 0 200 400 600 P2 P3 NDA Marketed Melinta / Menarini: Delaflo

  16. Slide 16: Rezafungin overall phase 3 development plan

    Slide 16: Rezafungin overall phase 3 development plan

    Rezafungin overall phase 3 development plan 1 Phase 3 Treatment Trial Phase 3 Prophylaxis Trial Treatment of candidemia & Prophylaxis against Aspergillus, Indication invasive candidiasis in patients Candida & PCP in allogeneic blood with limited treatment options and marrow transplant patients Phase

  17. Slide 17: The current standard of care is inadequate

    Slide 17: The current standard of care is inadequate

    The current standard of care is inadequate BMT patients discontinue prophylaxis due to adverse events and low tolerability 1 High Posaconazole 34% 1 discontinuation rate Fluconazole 38% 2 Bactrim 35% 90-day mortality in patients with invasive fungal infection3 High Blood and marrow transplant 63% mo

  18. Slide 18: Rezafungin: potential simplified single drug paradigm

    Slide 18: Rezafungin: potential simplified single drug paradigm

    Rezafungin: potential simplified single drug paradigm Antifungal prophylaxis in allogeneic blood and marrow transplant setting Fluconazole SOC for Current Fluconazole Posaconazole or Voriconazole Candida and Antifungal Aspergillus Prophylaxis or… Posaconazole or Voriconazole Regimens Bactrim, dapson

  19. Slide 19: ReSPECT Phase 3 prophylaxis trial design

    Slide 19: ReSPECT Phase 3 prophylaxis trial design

    ReSPECT Phase 3 prophylaxis trial design  Rezafungin Arm (n=~300) 1 Endpoint: Fungal Free Survival at Day 90 Follow up Week 1 2 3 4 5 12 13 17 Rezafungin Azole placebo Bactrim placebo Day 1 90 120 Comparator Arm (n=~150) Week 1 2 3 4 5 12 13 17 Rezafungin Placebo Azole* *Fluconazole to start in all

  20. Slide 20: COVID-19 patients at risk for fungal infections

    Slide 20: COVID-19 patients at risk for fungal infections

    COVID-19 patients at risk for fungal infections Working with KOLs to develop clinical protocol Challenge • COVID-19 patients at risk for secondary fungal infections • Similar to fungal infections seen in hospitalized flu patients Risk factors • Use of ventilator / intubation include: • Immunosuppres

  21. Slide 21: Cidara's pipeline targets multiple unmet medical needs

    Slide 21: Cidara's pipeline targets multiple unmet medical needs

    Cidara’s pipeline targets multiple unmet medical needs Rezafungin Cloudbreak 21

  22. Slide 22: Vision for Antiviral Conjugates for respiratory disease

    Slide 22: Vision for Antiviral Conjugates for respiratory disease

    Vision for Antiviral Conjugates for respiratory disease: Single-dose treatment and long-acting protection Against all strains… In all people… 22

  23. Slide 23: Cloudbreak platform – multimodal mechanism of action

    Slide 23: Cloudbreak platform – multimodal mechanism of action

    SB 10 Cloudbreak platform – multimodal mechanism of action Intrinsic antiviral activity & immune engagement Immune Pathogen Component TARGETING MOIETY (TM) Fc MOIETY • Inhibits essential surface target • Engages immune system • Direct viricidal activity • Extends PK 23

  24. Slide 24: Coronavirus AVCs are being designed to target viral fusion

    Slide 24: Coronavirus AVCs are being designed to target viral fusion

    Coronavirus AVCs are being designed to target viral fusion Untreated Treated 24

  25. Slide 25: Coronavirus - Novel Cloudbreak approaches to treat & prevent

    Slide 25: Coronavirus - Novel Cloudbreak approaches to treat & prevent

    Coronavirus - Novel Cloudbreak approaches to treat & prevent Inhibitor peptides Fc • Novel Fc - peptide fusion AVC inhibitors for SARS and COVID-19 • Goal: fast-acting treatment and long-acting prevention • 16 variants have been generated for first round of testing • Several designs under evaluation

  26. Slide 26: Potential Advantages of AVCs in COVID-19

    Slide 26: Potential Advantages of AVCs in COVID-19

    Potential Advantages of AVCs1 in COVID-19 Utility for rapid treatment and long-term prevention of respiratory diseases • Rapid onset of action • Superior distribution to lung • Months of protection from single dose • Activity in immune compromised hosts 1. The above have been observed in testing of

  27. Slide 27: CD377 for influenza: Validation of the approach in respiratory viruses

    Slide 27: CD377 for influenza: Validation of the approach in respiratory viruses

    SB 12 CD377 for influenza: Validation of the approach in respiratory viruses Broad spectrum, universal coverage Superior resistance profile Protection for High-Risk Populations Expanded efficacy window Long duration of action Rapid onset of activity Flexible administration 27

  28. Slide 28: CD377: a multivalent conjugate of a neuraminidase inhibitor with human Fc domain

    Slide 28: CD377: a multivalent conjugate of a neuraminidase inhibitor with human Fc domain

    SB 9 CD377: a multivalent conjugate of a neuraminidase inhibitor with human Fc domain AVC Direct inhibition of viral TM proliferation – NA inhibition Fc Virion HA NA Additional mechanisms – Additional mechanisms – Immune mediated clearance Improved antiviral activity vs small molecules NK/CD8+ cell

  29. Slide 29: Flu vaccines have well known limitations

    Slide 29: Flu vaccines have well known limitations

    SB 11 Flu vaccines have well known limitations… Viral coverage Patient Manufacturing Strain-specific, Less effective in elderly & Challenging in a pandemic: variable coverage immune compromised long, complex production 10%-60% effective ~2-week lag time to Difficult to scale, low yields (2004-2018)1

  30. Slide 30: Flu places a substantial burden on the US population

    Slide 30: Flu places a substantial burden on the US population

    … which place a substantial burden on the US population 49% 40% or less 9M to 45M immunization rate vaccine effectiveness people who get the flu 31.4M 140K – 810K 12K – 80K outpatient visits hospitalizations deaths The top range of these burden estimates are from the 2017-2018 flu season Sources: CD

  31. Slide 31: ~320M people should be vaccinated/year in US

    Slide 31: ~320M people should be vaccinated/year in US

    ~320M~320M peoplepeople shouldshould bebe vaccinated/yearvaccinated/year inin USUS OtherOther coco-morbiditiesmorbidities3 100100 1 1 4 ) 8080 FluFlu VaccineVaccine NonNon-believerbeliever M ( n o i t 6060 ElderlyElderly ageage 65+65+ a l u 2 p RespiratoryRespiratory coco-morbiditiesmorbidities o P

  32. Slide 32: CD377 development candidate profile

    Slide 32: CD377 development candidate profile

    CD377 development candidate profile Now in IND enabling studies Target Attribute CD377 Indication Universal prevention and treatment All data are supportive Spectrum A & B + drug resistant strains, low Potent in-vivo activity against resistance potential all seasonal and pandemic strains Safety/Tole

  33. Slide 33: AVC Clinical Development Plan (Phase 1a)

    Slide 33: AVC Clinical Development Plan (Phase 1a)

    AVC Clinical Development Plan (Phase 1a) Phase 1 Safety data to enable BARDA consideration . Phase 1a- SAD/MAD (~1-year duration) . 3 dose groups (10:3 ratio of CD377 : Placebo) low, medium & high dose . Total follow-up of ~4 months following last dose Screened Subjects N=52 Low Dose Subjects Mid Do

  34. Slide 34: Influenza Development Program: Treatment

    Slide 34: Influenza Development Program: Treatment

    Influenza Development Program Two Indications- Treatment and Prevention Treatment • Potential advantages based on nonclinical data over current standard of care • Efficacy against all tested strains of Influenza A and B (including H1N1, H3N1, H5N1, H7N9, etc) • Efficacy against oseltamivir- and balo

  35. Slide 35: Influenza Development Program: Prevention

    Slide 35: Influenza Development Program: Prevention

    Influenza Development Program Two Indications- Treatment and Prevention Prevention • Potential advantages based on nonclinical data over vaccines • Superiority in high-risk patients with low vaccine efficacy: elderly, cardiac/pulmonary patients, and diabetics, transplant, and other immunosuppressed

  36. Slide 36: Financial overview

    Slide 36: Financial overview

    Financial overview Summary Consolidated As of December 31, 2019 Balance Sheet Information As Reported Pro Forma Comment 1 PF includes rights offering Cash and restricted cash $60.3M $89.4M proceeds of $29.1M 2 PF includes Series X pref. Common stock issued 40.5M 51.5M shares ‘as converted’ Pacific W

  37. Slide 37: Cidara is much more than a typical ID company

    Slide 37: Cidara is much more than a typical ID company

    SB 12 Cidara is much more than a typical ID company Strategic Focus Transformative approaches to infectious disease Rezafungin Treatment Enable fast clearance of infection and early discharge vs SOC Rezafungin Prophylaxis Transform the care of BMT patients Cloudbreak AVC Radically different approach

  38. Slide 38: New Hope for Serious Infections

    Slide 38: New Hope for Serious Infections

    New Hope for Serious Infections 19th Annual Needham Virtual Healthcare Conference Corporate Presentation April 14, 2020 © Cidara Therapeutics 2020

Source: SEC EDGAR · 8-K filed Apr 14, 2020

More decks from Cidara Therapeutics Inc